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Abstract
The human malaria parasite Plasmodium falciparum is able to synthesize de novo pyridoxal 5-phosphate (PLP), a crucial
cofactor, during erythrocytic schizogony. However, the parasite possesses additionally a pyridoxine/pyridoxal kinase (PdxK)
to activate B6 vitamers salvaged from the host. We describe a strategy whereby synthetic pyridoxyl-amino acid adducts are
channelled into the parasite. Trapped upon phosphorylation by the plasmodial PdxK, these compounds block PLP-
dependent enzymes and thus impair the growth of P. falciparum. The novel compound PT3, a cyclic pyridoxyl-tryptophan
methyl ester, inhibited the proliferation of Plasmodium very efficiently (IC50-value of 14 mM) without harming human cells.
The non-cyclic pyridoxyl-tryptophan methyl ester PT5 and the pyridoxyl-histidine methyl ester PHME were at least one order
of magnitude less effective or completely ineffective in the case of the latter. Modeling in silico indicates that the
phosphorylated forms of PT3 and PT5 fit well into the PLP-binding site of plasmodial ornithine decarboxylase (PfODC), the
key enzyme of polyamine synthesis, consistent with the ability to abolish ODC activity in vitro. Furthermore, the
antiplasmodial effect of PT3 is directly linked to the capability of Plasmodium to trap this pyridoxyl analog, as shown by an
increased sensitivity of parasites overexpressing PfPdxK in their cytosol, as visualized by GFP fluorescence.
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Introduction
Malaria is one of the most threatening diseases in the world, with
more than 300 million infected people and up to 2 million fatalities
annually, mainly young children and pregnant women living in
Africa. The causative agent of the most severe form, tropical malaria,
is Plasmodium falciparum, a protozoan parasite that sequesters in the red
blood cells of its human host. As yet, there are no vaccines available
and the few antimalarials are losing their efficacy due to the rapid
spread of drug-resistant parasites. There is therefore an urgent need
to find new strategies to interfere with the parasite’s metabolism.
Pyridoxal 5-phosphate (PLP) is the active form of vitamin B6,
which comprises the vitamers pyridoxine, pyridoxal and pyridox-
amine as well as their related phosphate esters. It is a crucial cofactor
for various enzymatic reactions, predominantly involved in the
transformation of amino acids [1]. Many of the PLP-dependent
enzymes are essential and therein offer the possibility to target
diseases [2]. There are already promising attempts, such as the
inhibition of c-aminobutyric acid (GABA) aminotransferase by
vigabatrin in epilepsy therapy [3] or of alanine racemase by
antibacterial agents [4,5]. The PLP-dependent enzyme ornithine
decarboxylase (ODC) is a target in the fight against African
trypanosomes, the causative agent of sleeping sickness, and against
cancer [2,6,7]. ODC is the key enzyme in the formation of
polyamines, which are essential for cellular proliferation and
differentiation [8,9], and accordingly, polyamine biosynthesis in the
malaria parasite is also considered to be a possible drug target [10].
The reactions of PLP-dependent enzymes are highly diverse;
however the initial formation of a Schiff base of PLP with the amino
group of an amino acid is a common intermediate to all of them.
Reduction of the Schiff base leads to a covalent coenzyme-substrate
adduct resembling a transition-state analog with high affinity to the
apoprotein [11]. Over thirty years ago, Heller et al. [12] synthesized
several phosphopyridoxyl-amino acids that mimic the Schiff base
intermediate involved in enzymatic decarboxylation. Among these,
N-(5-phosphopyridoxyl)-ornithine inhibited rat liver ODC by
binding to the holoenzyme in a non-competitive manner with
respect to substrate and cofactor. Recently, a new analog, the BOC-
protected pyridoxyl-ornithine conjugate (POB), was shown to
inhibit human ODC in cells as well as the growth of various tumor
and transformed cells effectively, whereas non-tumorigenic cells
were less affected [13]. Another analog, pyridoxyl-histidine methyl
ester (PHME), was able to inhibit human histidine decarboxylase in
human mastocytoma cells without affecting proliferation [14].
Plants, bacteria, as well as some fungi are able to synthesize PLP de
novo, whereas mammals entirely depend on the dietary uptake of
pyridoxal, pyridoxine and pyridoxamine. They are converted into
PLP via phosphorylation by pyridoxal/pyridoxine kinase (PdxK; EC
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oxidase (EC 1.4.3.5). Although PdxK is widely distributed in human
tissues, oxidase activity is low or absent in most cells [15]. Human
erythrocytes have both enzymes and are proposed to be the main
carrier of vitamin B6. PLP in red blood cells is mostly bound to
proteins. To provide tissues with pyridoxal, PLP is dephosphorylated
by vitamin B6 specific phosphatase within the erythrocyte [16]. The
plasmodial parasite generates vitamin B6 de novo in its erythrocytic
stage [17,18]. The assembly of the plasmodial PLP-synthesis
machinery follows a hierarchically defined course, which seems to
be essential for activity [19]. In addition, the parasite possesses a
functional PdxK [17], which in other protozoan parasites that lack de
novo synthesis, such as trypanosomes, is the only enzyme activating
salvaged pyridoxal [20].
In this report we present a new approach to target the malaria
parasite by designing and testing novel pyridoxyl-adducts as
antimalarials. In a first step these compounds are trapped upon
phosphorylation in the parasite. In this state they mimic PLP and
together with the substrate moiety they bind and inhibit efficiently
PLP-dependent enzymes, which eventually kills the parasite. We
validate their potency as substrates of PfPdxK as well as their
inhibitory effect on the PLP-dependent enzyme PfODC, and
finally we demonstrate that the antiplasmodial effect can be
directly linked to the activity of the plasmodial PdxK as transgenic
parasites overexpressing PfPdxK exhibit an increased sensitivity
towards the pyridoxyl-analog.
Results
Pyridoxyl-amino acids are substrates of the plasmodial
PdxK
Our strategy is based on the fact that pyridoxal is phosphor-
ylated by the plasmodial PdxK and the resulting PLP is thereby
trapped within the parasite. In this respect the non-phosphorylated
pyridoxyl-adducts PT3, PT5 and PHME (shown in Figure 1; their
synthesis and that of their phosphorylated forms is described in the
section Supporting information, Text S1) were tested as potential
substrates of PfPdxK. All three pyridoxyl-adducts were phosphor-
ylated by the plasmodial enzyme with specific activities of 38, 20
and 64 nmol min
21 mg
21, respectively (Table 1).
Phosphorylated pyridoxyl-amino acids inhibit PfODC in
vitro
Phosphorylation of pyridoxal is required in order to obtain the
active cofactor for the enzymatic reaction of PLP-dependent
enzymes. The activity of ODC depends on PLP and its
competition by the pyridoxyl-adducts was measured as a
representative for PLP-dependent enzymes. The non-phosphory-
lated pyridoxyl-adducts, PHME, PT5 and PT3, did not inhibit the
plasmodial ODC activity in the standard in vitro assay (Table 1).
Only the phosphopyridoxyl-adducts PPHME and PPT5 act as
inhibitors on the plasmodial ODC with IC50-values of 58 mM and
64 mM, respectively, as shown in Table 1. Since PPT3 was not
available its inhibitory potential was analyzed by in silico modeling.
Structural analysis of PfODC binding to PPT3 and PPT5
The active species of PT3 and PT5 in cells are presumed to be
their phosphorylated forms. To study the binding mode in the
active site of plasmodial ODC and to elucidate binding
differences, PPT3 and PPT5 were modeled into the active site of
PfODC (Figure 2). The 5-phosphate-pyridoxyl motif forms
hydrogen bonds with Ser868B, Met967B, His998B and Tyr1384B
in both compounds. The side chains of both PPT3 and PPT5
occupy the pocket formed by Asp887B, Lys868B, Cys1355A,
Asn1393A, Arg1117B, Asp1320B, Asp1356A and the hydropho-
bic residues Tyr1384B, Tyr966B, Phe1392A. The indole ring of
PPT3 and PPT5 is engaged in hydrophobic interactions with
Tyr1384B. The N atom of the indole ring of the cyclic PPT3 can
Figure 1. Structures of the pyridoxyl-amino acid adducts PHME, PT5 and PT3. The phosphorylation sites are indicated by arrows.
doi:10.1371/journal.pone.0004406.g001
Table 1. PT3, PT5, PHME and their phosphate esters as
substrates of PfPdxK or inhibitors of PfODC
Compounds
Specific activity
of PfPdxK
(nmol min
21 mg
21)
a)
Inhibition of
PfODC activity
IC50-value [mM]
a)
PHME 6464 n.d.
PT5 2062 n.d.
PT3 3864 n.d.
PPHME n.d. 58611
PPT5 n.d. 64613
Pyridoxine
b) 11269
Pyridoxal
b) 5064
Pyridoxamine
b) 3062
a)All results represent the mean values6standard deviations of three to six
independent experiments; n. d.=not detectable.
b)Values are taken from [17].
doi:10.1371/journal.pone.0004406.t001
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non-cyclic PPT5 can form one with Asp1320B.
PT3 exhibits distinct antiplasmodial activity
To analyze the potential of the pyridoxyl-amino acid conjugates
in blocking the proliferation of cultured P. falciparum, the parasites
were treated with the non-phosphorylated forms. Additionally,
deoxypyridoxine, known to be effective against P. lophorae [21], was
tested as a control. While deoxypyridoxine and PHME had no
effect on parasite growth, PT3 inhibited the proliferation of
cultured Plasmodium with an IC50-value of 14 mM (Figure 3). PT5
also showed antiplasmodial activity, however, the apparent IC50-
value was more than one order of magnitude higher. The
phosphorylated compounds did not inhibit plasmodial growth at
all (data not shown). Interestingly, the effect of PT3 on the growth
of mammalian cells was marginal. At a concentration of 50 mM
PT3 the growth was decreased to about 75% of the untreated
control. Treating the cells with 100 mM PT3 only slightly
increased inhibition further (Table 2).
Localization of the PfPdxK
In order to determine the localization of the plasmodial PdxK,
the open reading frame of gfp was fused to the 39-end of pfpdxk
resulting in a PfPdxK-GFP chimera. Three weeks post-transfec-
tion, cells resistant to the selection drug WR99210 were obtained
and successful transfection of the construct was confirmed by
plasmid rescue (data not shown). The PfPdxK-GFP chimera
revealed an even distribution in the parasite’s cytosol (Fig. 4A) and
its expression was confirmed by western blot analysis showing a
band of the expected size of 82 kDa only in the transgenic cell line
(Fig. 4B).
P. falciparum overexpressing PfPdxK is more sensitive
towards PT3
Since PfPdxK presumably activates the prodrug PT3, thereby
triggering inhibition of parasite growth, another transgenic P.
falciparum cell line was created. This cell line overexpressed PfPdxK
fused to a C-terminal strep tag II encompassing ten amino acid
residues (PfPdxK-strep), thus avoiding possible steric influences of
the GFP protein. The expression of PfPdxK-strep was verified by
northern blot analysis of total RNA (Figure 5A). Additional to the
endogenous mRNA of about 3 kb, present in wild-type and
PfPdxK-strep parasites (a), a 4 kb band occurred only in the
transgenic PfPdxK-strep expressing cell sample (b). The corre-
sponding PfPdxK-strep protein was further verified by western blot
analysis, using a monoclonal antibody against the fused strep tag
(Figure 5B). To analyze the effect of PT3 on the transgenic
PfPdxK-overexpressing cells as well as on wild-type parasites,
proliferation was monitored over a period of 6 days. The
experiment clearly revealed that PfPdxK-overexpressing cells that
were treated with 7 mM PT3, corresponding to half the IC50-
value, exhibited a considerably increased doubling time (45.0 h,
calculated as described in Materials and Methods), in comparison
to untreated PfPdxK-strep cells (17.5 h). This parameter was only
Figure 2. Stereo view of the putative binding mode of PPT3 and PPT5 in the active site of PfODC. Residues surrounding the coenzyme-
substrate analogs within a distance of 3 A ˚ are indicated in cyan. PPT5 is colored in pink and the cyclic form PPT3 is colored in green and by default
atom types (O, N). The hydrogen bonds formed by PPT3 and PfODC are shown with green dotted lines.
doi:10.1371/journal.pone.0004406.g002
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control to 20.7 h for the culture treated with PT3 (Figure 6).
Discussion
The general lack of progress in malaria control depends not
least on account of resistance to common antimalarials [22]. In
this respect, not only the search for novel drug targets in the
parasite’s metabolism but also new approaches should be
considered to fight the parasite.
We propose here a strategy to poison PLP-dependent enzymes
in order to kill the human malaria parasite P. falciparum. PLP is a
cofactor in more than 140 distinct enzymatic reactions, corre-
sponding to approx. 4% of all classified activities [1]. Many of the
PLP-dependent enzymes are essential; once blocked, the death of
the parasite follows, as reported for the plasmodial ornithine
decarboxylase (PfODC) [10,23]. The idea behind the proposed
strategy is hence to target critical PLP-dependent enzymes of the
parasite simultaneously by using pyridoxyl-adducts as prodrugs.
Wu et al. [14] showed that the pyridoxyl-histidine methyl ester
(PHME) acts as a potent transition-state inhibitor of histidine
decarboxylase (hHDC) in human cells. When PHME was applied
to cultured P. falciparum no significant growth inhibition was
observed; similar to the result obtained with the pyridoxine analog
deoxypyridoxine, although the latter was previously reported to be
an effective inhibitor in a different system [21]. Either these two
compounds do not interfere sufficiently with the parasite’s
metabolism or have only a limited uptake. Since the erythrocyte,
the host cell that harbors Plasmodium, is regarded as the main
carrier of vitamin B6 in the human [15], the question arises
whether the strategy of poisoning PLP-dependent enzymes in the
parasite is at all applicable. However, it was shown that PLP is
immediately bound by hemoglobin [24] and hence of limited
availability for the parasite. It therefore remains to be clarified to
what extent the parasite relies on salvage, given that the de novo
synthesis of PLP seems to be functional in the blood stage, during
which Plasmodium can survive without additional pyridoxine [25].
In this study we present the newly synthesized pyridoxyl-
tryptophan methyl esters PT3 and PT5 (Figure 1). The cyclic PT3
exhibits an antimalarial effect in the low micromolar range, with
an IC50-value of 14 mM, whereas the non-cyclic PT5 is one order
of magnitude less effective (Figure 3). PT3 treatment of human
cells revealed only a moderate effect (as shown in Table 2),
suggesting that the impact of PT3 is parasite-specific. Moreover,
effective inhibition of Plasmodium at the cellular level with this
pyridoxyl-analog demonstrated that de novo synthesis of PLP is
unable to compensate for the adverse effect of PT3 on parasite
survival. While we assume that, in vivo, there is a dual provision to
the parasite’s PLP pool, further experiments concerning uptake
and functional analyses on knock-out parasites would have to be
performed to establish the contributions and relative importance
of salvage and de novo synthesis.
Table 2. Effect of PT3 on mammalian cell lines
Mammalian cell lines Growth inhibition (%)*
50 mM PT3 100 mM PT3
RD 74656 0 67
A 549 73686 5 68
FRHK 4 76667 3 69
*Of untreated control; all results represent the mean values6standard errors of
at least three independent experiments.
doi:10.1371/journal.pone.0004406.t002
Figure 3. Effect of PT3, PT5 and PHME on cultured Plasmodium. Proliferation was determined after 48 h incubation by the [
3H]-hypoxanthine
incorporation assay described in Material and Methods. The experiment presented is representative of at least three independent analyses each in
triplicate.
doi:10.1371/journal.pone.0004406.g003
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presented here show that both compounds, PT3 and PT5, are
phosphorylated by the PfPdxK in vitro at levels comparable to those
for the natural substrates pyridoxal and pyridoxamine (Table 1).
From this we assume that the pyridoxyl-analogs are likely to be
trapped in the parasite. Their trapping in the erythrocyte can be
discounted since, beside a PdxK, the host also possesses pyridoxal
phosphatase activities [16].
In order to examine whether the phosphorylated pyridoxyl-
amino acid adducts are able to interact with their assumed target
enzyme, the inhibitory effect on the plasmodial ODC activity was
measured. As expected, only the phosphorylated analogs inter-
fered with the decarboxylation of ornithine to putrescine and were
thus able to displace PLP in PfODC (Table 1). The fact that
pyridoxyl-histidine and -tryptophan inhibit ODC is contrary to the
generally accepted view that such transition state inhibitors should
be designed only as coenzyme-substrate adducts.
As PPT3 was not available, its inhibitory action on plasmodial
ODC could not be experimentally measured and thus its
interaction was studied in silico. Molecular modeling of PPT3
and PPT5 in the active site of PfODC predicted that these would
have different binding affinities to the enzyme. PPT3 forms
hydrogen bonds with Asp887B and Cys1355A of PfODC, whilst
PPT5 can form only one, with Asp1320 (Figure 2). The concerted
hydrogen bonding of the N atom of the indole ring of PT3 with
Asp887B and Cys1355A found in the modelled complex, which
results in an additional hydrogen bond in comparison to the
complex with PPT5, could account for the better binding of PPT3.
Whether this is the main contribution or whether additional
energetically favourable interactions are present is beyond the
scope of the present modelling studies. Notably, Cys1355A has
been assumed to be the catalytic residue in PfODC [26], with a
function comparable to Cys360 in mammalian [27] and
trypanosomal ODC [28]. Cys360 modification totally abolishes
ODC activity, as demonstrated with the well-known suicide
inhibitor DFMO [27].
The use of pyridoxyl-adducts as competitive transition-state
inhibitors has already been tried by many groups and their
potency confirmed [12,29]. However, using such compounds as
prodrugs against Plasmodium had not been tested so far. The
strategy proposed here is highly dependent on the phosphorylation
by PfPdxK to activate and trap the phosphorylated prodrug in the
Figure 4. Localization of PfPdxK-GFP in living parasites by fluorescence microscopy. A) Fluorescence of the GFP moiety (green) is found in
the parasite’s cytosol. The nucleus is stained with Hoechst dye (blue). B) Total protein homogenates of WT and PfPdxK-GFP parasites were separated
by SDS-PAGE and PfPdxK-GFP was visualized by western blot analysis using an anti-GFP antibody diluted 1:2000 (left panel) and 1:1000 (right panel).
doi:10.1371/journal.pone.0004406.g004
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overexpressing a transgenic copy of PfPdxK in the parasite. By
means of a GFP chimera, a cytosolic localization of PfPdxK -
important for trapping PT3 - could be observed (Figure 4). As GFP
might disturb the enzyme activity of PdxK, a construct carrying a
small strep tag (10 amino acids) instead of GFP (238 amino acids)
was also generated. Expression of the PfPdxK-strep fusion
product, previously shown to maintain PdxK activity [17], was
subsequently confirmed by western and northern blot analyses
(Figure 5). Since in this case PfPdxK is not the target enzyme but
the activator of the prodrug PT3, an increased sensitivity of
transgenic PfPdxK overexpressing cells would be expected relative
to wild-type. Consistent with the proposed strategy, monitoring
parasite growth over several days clearly revealed that the impact
of PT3 on PfPdxK overexpressing cells was considerably stronger.
The growth rate of these cells was reduced by 61% relative to the
untreated control (Figure 6B), whereas the proliferation of the
wild-type was only inhibited by 19% (Figure 6B). From that we
conclude that a time-dependent accumulation of PPT3 in the
parasite’s cytosol occurred, emphasizing the key role of PfPdxK.
Our results suggest that the pyridoxyl-tryptophan derivative
enters the parasite, possibly directly via an amino acid transporter.
After phosphorylation, PPT3 displaces PLP from the active site of
ODC (and other PLP-dependent enzymes) or binds directly to
newly synthesized apoenzymes which ultimately arrests growth of
P. falciparum (Figure 7). The significant superiority of the cyclic
form (PT3) compared to the open form (PT5) of pyridoxyl-
tryptophan in inhibiting proliferation of the parasite can be
explained by differences in binding of PfODC as indicated by the
molecular modeling studies.
The selective inhibition profile for proliferation achieved with
PT3 - IC50 of 14 mM for P. falciparum (Figure 3) and
IC50.100 mM for human cells (Table 2) - suggests that the
approach of poisoning Plasmodium with PLP-mimicking com-
pounds holds considerable promise. Further studies will be
required to show whether, besides ODC, additional plasmodial
enzymes are effectively targeted and to improve the prodrugs by
appropriate structural modifications.
Figure 6. Effect of PT3 on the growth of transgenic P.
falciparum. A) Wild-type as control (triangle) and B) PfPdxK-strep
overexpressing cells (diamond) were cultured with (filled) and without
(open) 7 mM PT3 for 150 h. Cumulative parasitaemias were calculated
by extrapolation from observed parasitaemias and the corresponding
dilution factors that were employed at each sub-culturing step. The
data consist of three independent monitorings plotted on a semi-
logarithmic scale with exponential regression shown as trend lines with
respective R
2-values.
doi:10.1371/journal.pone.0004406.g006
Figure 5. Analysis of PfPdxK-strep expression in P. falciparum. A)
RNA isolated from wild-type (WT) and transgenic PfPdxK-strep (PdxK)
cells was analyzed by a northern blot, on which beside the endogenous
pdxk (a) an additional band of approx. 4 kb was detected only in PdxK,
corresponding to the expected size of the exogenous transcript (b). B)
Total protein homogenates of WT and PdxK parasites were separated
by SDS-PAGE and the expression of PfPdxK-strep was visualized by
western blot analysis using an anti-strep antibody. C) The western blot
was reprobed with a specific anti-thiamine pyrophosphokinase (TPK)
antibody as loading control.
doi:10.1371/journal.pone.0004406.g005
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Materials
Restriction enzymes and ligase were purchased from New
England Biolabs, USA. Oligonucleotides were from Operon,
Germany. Strep-Tactin-Sepharose, anhydrotetracycline and
dethiobiotin were from IBA (Institut fu ¨r Bioanalytik, Germany).
Radioactive compounds: [U-
3H]-hypoxanthine, [c-
33P]-ATP and
[1-
14C]-L-ornithine were from GE Healthcare, Germany. All other
chemicals were from Sigma, Germany, unless otherwise stated.
Enzyme assays
Recombinant expression using an anhydrotetracycline inducible
system and affinity purification via strep tag of the plasmodial
PdxK as well as the bifunctional P. falciparum AdoMetDC/ODC
were carried out as described previously [30]. The enzyme assay of
the PfPdxK was performed in 70 mM potassium phosphate buffer,
pH 6.5, containing either 200 mM pyridoxine according to
Wrenger et al. [17] or up to 200 mM of the non-phosphorylated
pyridoxyl-adducts (PHME, PT5 and PT3), 5 mM MgCl2, 500 mM
(2 mCi
33P) ATP as well as 2.5 mg protein in a total volume of
100 ml. The reaction took place at 37uC for 1 h. The data were
analyzed using GraphPad Prism 4.0. PfODC activity was assayed
as described [26] by measuring the formation of
14CO2 from
[
14C]-L-ornithine at 37uC. The standard assay contained, in a
final volume of 250 ml: 40 mM Tris-HCl buffer, pH 7.5, 1 mM
dithiothreitol, 1 mM EDTA, 10 mM pyridoxal 5-phosphate,
100 mM (125 nCi
14C) L-ornithine and 2 mg recombinant
PfODC/AdoMetDC. The reaction occurred at 37uC for
30 min. The inhibitory effect, expressed as the IC50-value, of the
phosphopyridoxyl-adducts (PPHME and PPT5) was determined at
concentrations of 50, 100 and 200 mM.
Molecular modeling
The model structure of PfODC together with bound PLP and
DFMO [31] wasobtained fromthe protein data bank (http://www.
rcsb.org, PDB code: 1M9V). The active site model of PfODC with
PPT3 and PPT5 was generated on the basis of the known 3D
coordinates of the complex of PfODC with PLP-DFMO followed
by energy minimization with the InsightII/Built module (steepest
descents, up to a maximum derivative of 20 kcal/mol, consistent
valence force field, CVFF). The structures were further optimized
by energy minimization using the InsightII/Discover module
(conjugation gradient, until a maximum derivative of 0.01 kcal/
mol was reached, CVFF) according to Wu et al. [14].
Inhibition assays on cultured P. falciparum and
mammalian cells
P. falciparum 3D7-strain was maintained in continuous culture
according to Trager and Jensen as modified [23]. The parasites
were grown in human erythrocytes (O+), RPMI 1640 medium
supplemented with 25 mM HEPES, 20 mM sodium bicarbonate
and 0.5% AlbuMAX II (Invitrogen, Germany) at 4% hematocrit.
The cells were cultivated in 90 mm Petri dishes (Nunc, Denmark)
and incubated at 37uC in presence of 90% N2,5 %O 2 and 5%
CO2. The impact of deoxypyridoxine and the pyridoxyl-adducts
PHME, PT5 and PT3 on the erythrocytic stages of P. falciparum
was determined by using the [
3H]-hypoxanthine incorporation
assay as described [23] and the IC50-value of PT3 was calculated
from sigmoidal inhibition curves using GraphPad Prism 4.0.
Additionally, 50 and 100 mM PT3 was tested against human cell
lines RD and A 549 as well as the rhesus monkey cells FRHK 4
cultured in DMEM complete medium (PAA Laboratories, Austria)
containing 7.5% FCS (Invitrogen) at 5% CO2 for 48 h at 37uCi n
96 well plates. Cell viability was determined by incorporation of
[
3H]-hypoxanthine as described above using 10000 cells per well.
To analyze the long term effect of PT3 on the PdxK-
overexpressing and wild-type parasites, growth rates were
monitored for several days by light microscopy of Giemsa-stained
thin smears with a starting parasitaemia between 1 and 2%.
Growth curves were generated with GraphPad Prism 4.0 using an
exponential equation to calculate the slopes.
Figure 7. Schematic action of PT3. 1) Uptake of PT3 occurs either via a parasite specific transport system directly into the parasite or indirectly via
the host cytosol where PT3 might be phosphorylated and dephosphorylated by the human enzymes, PdxK and pyridoxal phosphatase, respectively.
2) Activation of PT3 upon phosphorylation by PfPdxK leads to an accumulation of the compound as PPT3 in the cell. 3) PPT3 competes with PLP for
binding in the active site of PfODC or other PLP-dependent enzymes. 4) Inhibition of crucial PLP-dependent enzymes, such as ODC, results in growth
arrest.
doi:10.1371/journal.pone.0004406.g007
PLP-Dependent Enzymes
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To overexpress the plasmodial PdxK in the parasite as a strep tag
II (strep) fusion protein or as a PfPdxK-GFP chimera, two constructs
were generated carrying pfpdxk fused to C-terminal strep or GFP,
respectively. The open reading frame of pfpdxk was amplified by PCR
from gDNA using the Expand Long Template PCR System (Roche
Molecular Biochemicals, Germany) and the specific oligonucleotides
PfPdxK-pARL-kpn-S (sense) 59-GAGAGGTACCATGAAGAAG-
GAAAATATTATCTCC-39 and PfPdxK-strep-avr-AS (antisense)
59-GAGACCTAGGCTATTTTTCGAACTGCGGGTGGCTCC
AAGCGCTAAAAAAAACAGGCTCTTCTTTAATTAAAATA-
TC-39 for the strep (underlined) fusion protein and PfPdxK-pARL-
avr-AS (antisense) 59-GAGACCTAGGAAAAAAAACAGG-
CTCTTCTTTAATTAAAATATC-39 for the PfPdxK-GFP chime-
ra to obtain a 1451 bp or 1484 bp fragment, respectively, comprising
the full pfpdxK ORF without the stop codon and with strep,
respectively. The fragments were cloned into pARL1a- [32]
containing GFP with KpnI and Avr II restriction enzymes (bold)
resulting in the constructs pARL-PfPdxK-strep and pARL-PfPdxK-
GFP. Both constructs were confirmed by automated sequencing on
an ABI 377 (Applied Biosystems Inc., Germany) and the plasmid
DNA for transfection was obtained using a Maxi Prep Kit (Qiagen,
Germany). Prior to transfection, parasites weresynchronized with 5%
sorbitol [33] and cultivated for at least one additional cycle of
schizogony. Transfection was carried out by spontaneous uptake of
DNA [34]. Before electroporation, 400 ml red blood cells were
washed in cytomix [35] and mixed with 100 mg circular plasmid
DNA dissolved in 30 ml Tris-EDTA. Electroporation was performed
in a 0.2 cm gap cuvette (Biorad, Germany) at 310 V and 900 mFi n
an EasyJect Gene Pulser (EquiBio, Germany). Red blood cells pre-
loaded with DNA in this way were transferred into prewarmed
medium and provided with 50 ml red blood cells infected with 10%
schizonts. The next day the culture medium was supplemented with
5 nM WR99210 (Jacobus Pharmaceutical Company, USA) as the
selectiondrug.ThePfPdxK-strepparasitesobtainedweremaintained
in 50 nM WR99210 to induce overexpression of the PfPdxK-strep
fusion protein.
Analysis of transgenic parasites
Wild-type and PfPdxK-strep overexpressing parasites were
separated from the host cell with saponin [36] and kept at
220uC for protein isolation or resuspended in Trizol (Invitrogen)
for RNA extraction according to the manufacturer’s instructions;
25 mg total RNA were analyzed by northern blotting [37] using a
radiolabeled pfpdxk-probe. Total plasmodial protein extract was
obtained by boiling the parasites at 95uC for 5 min in an SDS- and
mercaptoethanol-containing buffer. Equal amounts (15 mg) were
separated on 10% SDS-PAGE and subsequently transferred to a
nitrocellulose membrane (Schleicher & Schu ¨ll, Germany). Expres-
sion of PfPdxK-GFP and of PfPdxK-strep was analyzed using
either a polyclonal anti-GFP antibody (1:1000 and 1:2000;
Invitrogen) or a monoclonal anti-strep antibody (1:5000; IBA)
and HRP-coupled secondary anti-rabbit or anti-mouse antibodies
(1:10000; Invitrogen, Germany), respectively. The blot was
stripped and reprobed with a polyclonal antibody against
plasmodial thiamine pyrophosphokinase (TPK) (1:10000; [38])
and the secondary anti-rabbit HRP coupled antibody (1:10000,
Dianova, Germany). The detection was performed using ECL
(Millipore, Germany). The green fluorescence of the PfPdxK-GFP
chimera was detected and captured in live cells using a Zeiss
Axioskop 2 and the OpenLab software (Improvision, Germany).
The parasite’s nuclei were visualized with 0.2 mg/ml Hoechst
33342 dye (Invitrogen, Germany).
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0004406.s001 (0.02 MB
DOC)
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